Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | SCN1A | P35498 | 1/20 | 0.42 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.42 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21753093 | 0.89 | FOLH1 (0.51) | FOLH1ALDH1A1TSHRHTTKMT2A | |
| SCHEMBL30128417 | 0.89 | FOLH1 (0.51) | FOLH1ALDH1A1TSHRHTTKMT2A | |
| SCHEMBL5682890 | 0.87 | KMT2A (0.45) | FOLH1ALDH1A1TSHRHTTTP53 | |
| SCHEMBL293291 | 0.87 | L3MBTL1 (0.57) | FOLH1ALDH1A1TP53SMN1; SMN2TDP1 | |
| SCHEMBL23043892 | 0.87 | ALDH1A1 (0.47) | FOLH1ALDH1A1TSHRHTTKMT2A | |
| SCHEMBL8791191 | 0.84 | ALDH1A1 (0.56) | FOLH1ALDH1A1TSHRHTTTP53 | |
| SCHEMBL31245538 | 0.81 | FOLH1 (0.56) | FOLH1ALDH1A1TSHRHTTTP53 | |
| SCHEMBL3966145 | 0.81 | FOLH1 (0.56) | FOLH1ALDH1A1TSHRHTTTP53 | |
| SCHEMBL9323033 | 0.80 | FOLH1 (0.54) | FOLH1ALDH1A1TSHRHTTTP53 | |
| SCHEMBL16244982 | 0.80 | FOLH1 (0.54) | FOLH1ALDH1A1TSHRHTTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2727915-B1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | CONCERT PHARMACEUTICALS INC (US) | 2016-04-13 | — | — | EP | claimed |
| EP-2727915-A1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | Concert Pharmaceuticals Inc. (US) | 2014-05-07 | — | — | EP | claimed |
| EP-4419513-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2025-08-27 | — | — | EP | disclosed |
| EP-4604951-A1 | 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF | AMIRA THERAPEUTICS, S.L. (ES) | 2025-08-27 | — | — | EP | disclosed |
| US-12384800-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2025-08-12 | — | — | US | disclosed |
| US-20250243174-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2025-07-31 | — | — | US | disclosed |
| WO-2025077996-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS | PHARMA MAR, S.A. (ES) | 2025-04-17 | — | — | WO | disclosed |
| WO-2025050647-A1 | IONIZABLE CATIONIC LIPID COMPOUNDS AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | 晟迪生物医药(苏州)有限公司 | 2025-03-13 | — | — | WO | disclosed |
| US-12215100-B2 | Anticancer compounds | PHARMA MAR, S.A. (ES) | 2025-02-04 | — | — | US | disclosed |
| EP-4419513-A1 | ANTITUMORAL COMPOUNDS | Pharma Mar S.A. (ES) | 2024-08-28 | — | — | EP | disclosed |
| US-20240279248-A1 | SYNTHESIS OF BORONATE ESTER DERIVATIVES AND USES THEREOF | MELINTA SUBSIDIARY CORP. | 2024-08-22 | — | — | US | disclosed |
| EP-1485707-A4 | CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS | HK PHARMACEUTICALS INC (US) | 2005-11-16 | — | — | EP | disclosed |
| EP-1583972-A2 | CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS | HK Pharmaceuticals, Inc. (US) | 2005-10-12 | — | — | EP | disclosed |
| US-20050042771-A1 | Identifying non-drug targets; use in drug design for improving knowledge of drug-target and drug-non-target interactions, so that drug adverse reactions can be reduced or eliminated in drugs such as troglitazone, rosiglitazone, pioglitazone, methotrexate, atorvastatin, celecoxib, rofecoxib, cerivastatin | CAPROTEC BIOANALYTICS GMBH (DE) | 2005-02-24 | — | — | US | disclosed |
| EP-1485707-A2 | CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS | HK Pharmaceuticals, Inc. (US) | 2004-12-15 | — | — | EP | disclosed |
| WO-2004064972-A9 | CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS | HK PHARMACEUTICALS INC (US) | 2004-09-16 | — | — | WO | disclosed |
| WO-2004064972-A2 | CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS | HK PHARMACEUTICALS, INC. (US) | 2004-08-05 | — | — | WO | disclosed |
| WO-2003092581-A9 | CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS | HK PHARMACEUTICALS INC (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2003092581-A2 | CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS | HK PHARMACEUTICALS, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
| US-20030119021-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | CAPROTEC BIOANALYTICS GMBH (DE) | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384800-B2 | Antitumoral compounds | TP53, TOP1, MCL1 | FOLH1 178/4885ALDH1A1 144/4885TSHR 4670/4885 |
| US-20250243174-A1 | ANTITUMORAL COMPOUNDS | MCL1, XPOT, GZMB | FOLH1 589/4885ALDH1A1 318/4885TSHR 3614/4885 |
| US-20240279248-A1 | SYNTHESIS OF BORONATE ESTER DERIVATIVES AND USES THEREOF | ADH5, ADH1A, ADH7 | FOLH1 1952/4885ALDH1A1 69/4885TSHR 2507/4885 |
| US-12215100-B2 | Anticancer compounds | TP53, MCL1, MYC | FOLH1 1013/4885ALDH1A1 795/4885TSHR 4635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.